Disrupting the immunosuppressive myeloid microenvironment unlocks the next era of cancer immunotherapy

Pablo joined Criteria Bio Ventures in 2018, where he plays a pivotal role in Criteria Bio Ventures' Investment Team, leveraging his extensive experience as a life science investor. He serves as a board director at AbolerIS Pharma, Minoryx Therapeutics, MedLumics, and Aelix Therapeutics, and has held positions on various portfolio company boards including SANIFIT Therapeutics, Splice Bio, iProteos, GlyCardial Diagnostics, and AptaTargets. Before joining Criteria Bio Ventures, Pablo served as Head of the Technology and Business Development Office at the Centre for Genomic Regulation (CRG) from 2013 to 2018. During his tenure, he spearheaded the CRG’s Innovation and Business Strategy, focusing on strategic planning and implementation. Pablo earned his degree in Chemistry from the University of Buenos Aires, followed by a Ph.D. in Organic Chemistry from the University of Barcelona. He conducted postdoctoral research in Synthetic Biology at Harvard Medical School, where he explored new classes of protein-based therapeutics.

Ruben is a Senior Associate at Criteria Bio Ventures and focuses on building and investing in biotech companies. Ruben is board director at Adaptam Therapeutics, board observer at AbolerIS Pharma, and has been the due diligence lead on Tolerance Bio. Before joining Criteria Bio Ventures, Ruben was a Technology and Business Development fellow at the Centre for Genomic Regulation (CRG) technology transfer office, where he advised entrepreneurs on R&D, intellectual property protection, and commercialization strategies. He also provided due diligence support in biopharma and therapeutics deals as an independent consultant to early-stage investment firms in Spain and the US. Ruben holds a Ph.D. in Biomedicine from the Centre for Genomic Regulation (CRG), where he studied genome organization and epigenetics in stem cells and during cellular reprogramming and contributed to developing novel cell therapies with engineered chemokines for regenerative medicine, and a master’s degree in Cancer Biology from the University of Barcelona.

José M is a Board Member at Adaptam Therapeutics. He is the founder and General Director of the Centers CIC bioGUNE in Bilbao and CIC biomaGUNE in San Sebastián, and Research Professor at the Spanish National Research Council (CSIC). José M holds a Ph.D. in Biochemistry from Leiden University, where he was awarded the prestigious CJ Kok prize for his thesis. He completed postdoctoral training at the Biozentrum of the University of Basel and the National Institutes of Health. Throughout his career, José M has held various academic positions, including faculty member at the Jiménez Díaz Foundation in Madrid, Professor at the Faculty of Medicine of the University of Navarra, and Visiting Professor at the University of Pennsylvania and Thomas Jefferson University. From 1992 to 1996, he served as President of the CSIC and was honored with the Spanish National Research Prize in Medicine in 2004.